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Abstract: The exponential growth in the use of dental implants in the last decades has been accom-
panied by an increase in the prevalence of peri-implant disease. It appears that viruses may have
pathogenic potential for the development of this pathology. The objective of this systematic review is
to study the possible association between the presence of Epstein–Barr virus and the development
of peri-implantitis. An electronic search was conducted in PubMed/MEDLINE, Scielo and Embase
databases for cross-sectional and case–control studies in humans published up to and including
4 January 2021. Five studies were included in the qualitative analysis. The meta-analysis did not show
a statistically significant difference regarding the prevalence of Epstein–Barr virus in the peri-implant
sulcus between implants with peri-implantitis and healthy implants. In conclusion, no association
between the human herpesvirus 4 and peri-implantitis was found. Further research on this topic is
essential to develop more effective treatments.
Keywords: peri-implantitis; Epstein–Barr virus; human herpesvirus 4; peri-implant disease; dental
implants; peri-implant pathology; viruses
1. Introduction
In the last decades, the use of dental implants has increased significantly, suffering
an exponential growth since the first decade of the 21st century [1–3]. In fact, a study
carried out in the United States found that between 1999 and 2016 the prevalence of dental
implants increased by 14% per year and projection estimates suggest that it could be as
high as 23% by 2026 [3].
According to the scientific literature, dental implants show survival rates of up to 98%
at 10 years [4–6]. However, the higher use of dental implants has been accompanied by an
increase in the prevalence of peri-implant pathology [7]. A recent systematic review and
meta-analysis reported an incidence of peri-implantitis ranging from 0.4% over 3 years, to
43.9% within 5 years after implant restoration [8].
Besides minor prosthetic complications (such as crown loosening or ceramic chipping),
which are easy to solve, peri-implantitis is the most frequent complication and its resolution
is a real challenge, the reason why so much has been published in recent years on this
topic [9]. This pathology is defined clinically as the presence of signs of bleeding and/or
suppuration in the peri-implant tissues on probing, increased probing depth and loss of 2 or
more millimetres of marginal bone compared to previous radiographic recordings [7,10].
Its appearance is the result of a discrepancy between the bacterial challenge and the host
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response [11]. A large number of risk factors and indicators have been associated with
peri-implant disease, like smoking or diabetes mellitus [12–15], but bacterial infection plays
the most important role in its development [8,16,17]. Among the strains most frequently
related to peri-implant disease there can be found Aggregatibacter actinomycetemcomitans,
Prevotella intermedia, Tannerella forsythia, Treponema denticola, Campylobacter rectus, Treponema
socranskii, Porphyromonas gingivalis, Staphylococcus aureus, and Campylobacter gracilis [7,9,18].
However, it has been observed that other pathogens such as Candida spp. or some viruses
have an important pathogenic potential in the appearance and evolution of peri-implant
disease [7,19,20]. Growing evidence suggests that Epstein–Barr virus (EBV) plays a role in
the pathogenesis of periodontitis and peri-implantitis [21]. EBV is an enveloped herpesvirus
with double-stranded DNA, and it is estimated to infect more than 90% of the adult
population [19]. It is known that EBV is transmitted from host to host by salivary contact
and the virus passes through the oropharyngeal epithelium to B lymphocytes, where it
establishes a lifelong latent infection [19,22–24].
EBV can induce inflammatory process, being related to autoimmune diseases like
systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis [25] and is
nowadays associated with 1% of global cancers, mostly lymphomas and carcinomas [24].
The hypothesis than EBV may be related to peri-implant disease appears when the
presence of EBV is discovered in a high percentage in subgingival plaque samples from
periodontal patients [26] or in the peri-implant sulcus [18,21]. Additionally, reduction in
subgingival EBV levels following periodontal treatment was demonstrated as well [27].
Therefore, the virus may deteriorate immunologic stability in periodontal/peri-implant
disease by contributing to the overgrowth and aggressiveness of inflammophilic bacte-
rial periopathogens, thus favoring the initiation and progression of peri-implant tissues
breakdown [27,28]. Actually, the EBV and bacterial periopathogens interaction is bidirec-
tional [29], as specific anaerobic bacteria structural components have the ability to stimulate
EBV and the virus may influence pathogenic bacteria overgrowth by affecting potential
adhesion to infected host cells and altering the inflammatory cells involved in the immune
response [30,31].
The objective of the present systematic review is to study the possible association
between EBV and the development of peri-implantitis.
2. Materials and Methods
This systematic review was conducted according to the guidelines of the Preferred
Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) statement [32].
2.1. PECO Question (Population, Exposure, Comparison, Outcome)
P: Patients with at least one dental implant.
E: Peri-implantitis.
C: Healthy implants.
O: Prevalence of Epstein–Barr virus.
2.2. Eligibility Criteria
Studies were eligible for inclusion if they met the following criteria:
• Cross-sectional studies and case–control studies.
• Written in English or Spanish.
• That evaluated the correlation between Epstein–Barr virus and the presence
of peri-implantitis.
• Minimum sample of 20 implants.
• Peri-implantitis implants group (test) and healthy implants group (control).
• Peri-implant health diagnosis: radiological evaluation of bone loss and assessment of
at least one clinical parameter.
• Systemically healthy subjects.
• No history of antibiotic therapy for at least three months.
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2.3. Search Strategy
An electronic search was conducted by two reviewers (E.R.-M. and J.D.-M.) in MED-
LINE (PubMed), Embase and Scielo on 4 January 2021 for articles published up to that date.
An additional hand search was performed to identify potential articles of interest in the
references of the studies found in the electronic search. The following term combination
was used: (“epstein barr virus [All Fields]” OR “human herpesvirus 4 [All Fields]”) AND
(“peri-implantitis [All Fields]” OR “peri-implant diseases [All Fields]”).
2.4. Study Selection
After discarding duplicate articles, titles and abstracts were read to verify that the
identified articles met the inclusion criteria. Finally, the full text of the selected articles
was read to corroborate that they met the inclusion and exclusion criteria. Disagreements
during the study selection were solved by consulting a third author (J.L.-L.).
2.5. Data Extraction
Data were collected by an author (E.R.-M.) and entered into a data collection form and
later they were verified by a second author (J.L.-L.). The following data were extracted:
author(s), year of publication, type of study, number of total dental implants, number
of healthy implants, number of peri-implantitis implants, number of mucositis implants,
Epstein–Barr virus prevalence, sample origin, and main findings.
2.6. Quality Assessment
The Newcastle–Ottawa Quality Assessment Form for Case–Control Studies and the
Newcastle–Ottawa Quality Assessment Form Adapted for Cross-sectional Studies were
implemented to evaluate the methodological quality of the included articles [33]. Two
authors (E.R.-M. and J.D.-M.) independently assessed the studies and any discrepancies
were solved consulting a third author (J.L.-L.). The Newcastle–Ottawa Scale (NOS) judges
the quality considering three domains: selection of study groups, comparability of the
groups and outcome/exposure. The maximum score is 9 points for case–control studies
and 10 points for cross-sectional studies.
2.7. Statistical Analysis
Review Manager (RevMan) (computer program, version 5.4, The Cochrane Collab-
oration, 2020) was used to evaluate the association between the presence of EBV in the
peri-implant sulcus and the peri-implant tissues health. The Mantel–Haenszel random-
effects model was implemented in the meta-analysis. The level of significance was set at
p < 0.05. Heterogeneity was assessed with Chi2 and I2 tests.
3. Results
3.1. Study Selection
A total of 28 studies were identified through the electronic and manual searches.
Half of them were excluded due to duplication. Of these 14 articles, five were discarded
after reading the titles and three after reading the abstract as they did not meet the in-
clusion criteria. Of the six full-text articles with potential for inclusion [18,19,21,27,34,35],
one was excluded as it appeared to be the same study as another included paper but
in earlier stage [18]. Finally, a total of five studies were included in the qualitative
analysis [19,21,27,34,35] (Figure 1).
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram of selection process.
3.2. Study Methods and Characteristics
Three of the included articles were cross-sectional studies [21,27,35] and the other two
were case–control studies [19,34] (Table 1). The papers were published between 2011 and
2018. Three of them were conducted in training centers [19,21,27], one in a private dental
clinic [35] and another one does not specify where it took place [34]. A total of 274 patients
(149 women and 125 men) and 388 implants (197 healthy implants, 166 peri-implantitis
implants and 25 mucositis implants) were included in the analysis. In all the studies
samples were taken to perform a real-time polymerase chain reaction (PCR) to detect the
presence of EBV. In two of the articles only subgingival plaque samples of the peri-implant
tissues were extracted [19,21], in another one the source of the sample was saliva [34], in
another samples were taken both from saliva and subgingival peri-implant tissues [35]
and in the last one samples were extracted from subgingival plaque and from the internal
implant connection [27]. Only one study differentiated between EBV genotypes (EBV-1
and EBV-2) [21].
3.3. Quality Assessment
All the studies were assessed using the Newcastle–Ottawa Scale (NOS) [33]. The
comparability was the dimension that received the lowest score, while the evaluation of
the outcome/exposure was the one that obtained the highest (Table 2). The mean NOS
score was 6.6 (±1.34). Two of the studies can be considered of good quality [21,27] and the
other three of satisfactory quality [19,34,35].
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Abbreviations: EBV, Epstein–Barr virus; HI, healthy implants; MI, mucositis implants; PI, peri-implantitis implants.
Table 2. Quality assessment of the included studies according to the Newcastle–Ottawa Scale (NOS).
Selection Comparability Outcome/Exposure
Jankovic et al., 2011 [21] ??? ?? ???
Verdugo et al., 2015 [35] ??? ???
Kato et al., 2017 [19] ?? ? ???
Canullo et al., 2018 [27] ??? ?? ???
Marques et al., 2018 [34] ?? ? ??
* A star is awarded for each item within the Selection and Outcome/Exposure categories. A maximum of two stars can be given
for Comparability.
3.4. EBV and Peri-Implantitis
In three of the included studies, no statistically significant difference was observed
in the prevalence of EBV between patients with peri-implantitis (PI) and patients with
healthy implants (HI) [19,27,34]. However, in two of them the PI group presented higher
prevalence of EBV [19,34], with no difference in the third study [27].
In the other two works [21,35], statistically significant differences were found in the
prevalence of the virus between both groups. The group with PI showed a significantly
higher prevalence of EBV compared to the HI group. Jankovic et al. [21] observed this
result for EBV-1 genotype not for EBV-2 genotype.
Only one of the studies included also subjects with mucositis, a reversible peri-implant
pathology characterized by gingival inflammation without associated bone loss. In that
article a statistically significant correlation between the presence of EBV-1 and mucositis
was also found [21].
In cases where samples were extracted from two different sites, more EBV positives
were obtained from subgingival plaque above the saliva [35] or the internal implant
connection [27].
In relation to the association between EBV and other periopathogens, significantly
higher median loads of P. intermedia and C. rectus were found in EBV positives compared
to EBV negatives [27]. Furthermore, the coexistence between P. gingivalis and EBV was
statistically significantly higher in patients with peri-implantitis [19].
Regarding the inflammatory response, a statistically significant association was found
between the presence of herpesvirus and the presence in saliva of the markers macrophage
inflammatory protein-1β (MIP-1β) and tumor necrosis factor-α (TNF-α) in the PI group [34].
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3.5. Quantitative Analysis
Studies in which subgingival plaque samples were taken were selected for the quanti-
tative analysis [19,21,27,35]. No statistically significant difference was found regarding the
presence of EBV in the peri-implant sulcus between PI and HI groups (OR = 4.14; 95% CI:
0.93–18.37; z = 1.87; p = 0.06) (Figure 2). Heterogeneity tests from pooled showed statistical
significance (Chi-squared = 11.96, p < 0.008) (Figure 2).
Figure 2. Forest plot of the prevalence of Epstein–Barr virus (EBV) in peri-implantitis implants versus healthy implants.
4. Discussion
In the present meta-analysis no statistically significant difference was found regarding
the presence of EBV in the peri-implant sulcus between implants with peri-implantitis
and healthy implants. However, it must be considered that due to the limited literature
published on this topic, only four articles [19,21,27,35] could be included in the quantitative
analysis and the one with a larger sample and therefore greater weight is the study in
which no differences between groups were observed [27].
Only one of the studies evaluated both EBV genotypes, obtaining significantly higher
prevalence of the EBV-1 genotype in the PI group, which was not the case with the EBV-2
genotype [21]. This suggests that this genotype could be more present in the development
of peri-implant pathology. According to the same study, the development of mucositis
could already be encouraged by the presence of EBV-1 [21].
The higher prevalence of the virus in the peri-implant sulcus than in saliva of the same
subjects highlights the possible role of EBV in peri-implant diseases [35]. Furthermore, the
coexistence of the virus with periopathogenic bacteria such as P. gingivalis [19], P. intermedia
or C. rectus [27] could be a key point in the development of peri-implantitis.
Regarding the pathogenesis, it seems that the presence of EBV could be related to an
increase in the inflammatory response with the consequent increase in markers such as the
macrophage inflammatory protein-1β (MIP-1β) and tumor necrosis factor-α (TNF-α) [34].
There is no review so far that specifically focused on the relationship between EBV
and peri-implantitis, but there are three recent reviews that study the microbiological
profile of peri-implantitis [36] or the association of viruses [37], or more explicitly the
herpesvirus [38], with the appearance of this pathology.
One of these reviews concluded that the microbiological profile in peri-implantits
consists of Gram-negative anaerobic periopathogens and opportunistic microorganisms
almost in the same proportion and that is often associated with EBV [36]. Another review
concluded that the presence of herpesvirus in the peri-implant subgingival biofilm is an
indicator of peri-implant disease [38].
Unlike the present review, the only existing meta-analysis did find a statistically
significant difference in the presence of EBV between the PI and HI groups. However,
this difference between the two meta-analyses is based solely on the inclusion of a single
different article in the quantitative analysis [37].
The main limitation of this review is the limited scientific literature published on
this topic, which makes it impossible to draw conclusions about the possible association
between EBV and peri-implantitis. Furthermore, some of the included studies analyze
small samples or may represent a source of bias, especially due to the lack of information
on comparability between groups.
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Future research in this area should focus on case–control studies, with large samples,
with a higher methodological quality to reduce the risk of bias and in which samples were
obtained from the peri-implant sulcus and not from saliva or from the implant connection.
5. Conclusions
No statistically significant difference was found in terms of the prevalence of EBV
in the peri-implant sulcus between PI and HI groups. More case–control studies of high
methodological quality are necessary to evaluate the possible association between EBV
and peri-implantitis. Due to the high prevalence of periodontal disease and its difficult
treatment, it is essential to continue researching this topic, since better knowledge of its
pathogenesis will allow the development of more effective therapies.
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